A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：ALZHEIMERS RESEARCH & THERAPY ISSN： 1758-9193 出版频率： Continuous publication 出版社： BMC, CAMPUS, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW   出版社网址： http://www.biomedcentral.com/ 期刊网址： http://alzres.com/ 影响因子： 6.982 主题范畴： CLINICAL NEUROLOGY;    NEUROSCIENCES 变更情况： Newly Added by 2013 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal 4.39 About Alzheimer's Research & Therapy Aims and scope | Open access | Article-processing charges | Indexing services | Publication and peer review process | Editorial policies | Citing articles in Alzheimer's Research & Therapy | Why publish your article in Alzheimer's Research & Therapy? This page includes information about the aims and scope of Alzheimer's Research & Therapy, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors. Aims & scope Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases. Open access All Research articles and Open comments articles published by Alzheimer's Research & Therapy are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here. In addition, the journal also publishes reviews and other article types that are only available by subscription. Authors of Research articles and Open comments articles published in Alzheimer's Research & Therapy are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement. For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed. Other content In addition to research articles Alzheimer's Research & Therapy also publishes Commentaries, Debates, Meeting reports, Reviews and Viewpoints all of which are only available by subscription. BioMed Central holds the copyright to such subscription content according to the terms of BioMed Central's Copyright Licensing Agreement. Article-processing charges Open access publishing is not without costs. Alzheimer's Research & Therapy therefore levies an article-processing charge of £1290/$2110/€1550 for each Research articles and Open comments article accepted for publication. We routinely waive charges for authors from low-income countries. Generally, if the submitting author's institution is a Member the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. For further details, see our article-processing charge page. A limited number of waivers for article-processing charges are also available at the editors' discretion, and authors wishing to apply for these waivers should contact the editors. Indexing services All articles published in Alzheimer's Research & Therapy are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Alzheimer's Research & Therapy include: CAS Current contents DOAJ Embase Journal Citation Reports/Science Edition PubMed PubMed Central Science Citation Index Expanded Scopus The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands). Alzheimer's Research & Therapy is tracked by Thomson Reuters (ISI) and has an Impact Factor of 4.39. Publication and peer review process Criteria for publication Research articles: reports of data from exceptional original research. These articles will form the major content of the journal. Reviews: provide a factual account of recent developments within an area of research. Most are commissioned, though suggestions of topics are always welcome. In-depth reviews provide substantial coverage of a subject in a single longer article, and multi-author thematic series explore a subject in a series of concise, narrowly focused review articles coordinated by a leading authority in the field. Commentaries: short, focused and opinionated articles of contemporary interest on any subject within the journal's scope. Most are commissioned, although unsolicited commentaries are welcome and are routinely peer reviewed. Letters: may discuss material published in Alzheimer's Research & Therapy or particular issues of general interest to the readership. They may also present a community announcement within the field. Meeting Reports: short descriptions of a conference that an author has attended, which should focus on the key developments presented and discussed at the meeting. These articles are usually commissioned but reports and suggestions may also be submitted for the editors' consideration. Viewpoints: short opinion pieces focusing on the latest high-impact research. Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Alzheimer's Research & Therapy, a personalized section of the site. Copyediting and proofs All articles published in Alzheimer's Research & Therapy are copyedited before publication of the final version. Research articles and Open comments articles published in Alzheimer's Research & Therapy are published immediately on acceptance in the form of a provisional PDF. Copyedited and fully formatted PDF and full-text (HTML) versions are made available shortly after that. Edited versions will be sent by email and corrections should be returned within two working days. Please provide a typed list of corrections clearly indicating where the corrections should be made and please send this list by email. The editing of Research articles and Open comments articles is designed only to correct such things as misused words, spelling errors, missing references or incomplete citation information. Reprints High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints. Supplements Alzheimer's Research & Therapy will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us. Editorial policies All manuscripts submitted to Alzheimer's Research & Therapy should adhere to BioMed Central's editorial policies. Citing articles in Alzheimer's Research & Therapy Articles in Alzheimer's Research & Therapy should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number. Article citations follow this format: Authors: Title. Alzheimers Res Ther [year], [volume number]:[article number]. e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Alzheimers Res Ther 2009, 1:115. refers to article 115 from Volume 1 of the journal. Why publish your article in Alzheimer's Research & Therapy? High visibility Alzheimer's Research & Therapy's open access policy allows maximum visibility of research articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results. Speed of publication Alzheimer's Research & Therapy offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles are published with their final citation immediately upon acceptance in a provisional PDF form. The article will subsequently be published in both fully browsable web form, and as a formatted PDF; the article will then be available through Alzheimer's Research & Therapy, BioMed Central and PubMed Central and will also be included in PubMed. Flexibility Online publication in Alzheimer's Research & Therapy gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles). Promotion and press coverage Articles published in Alzheimer's Research & Therapy are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Alzheimer's Research & Therapy's pages and on the BioMed Central homepage. In addition, articles published in Alzheimer's Research & Therapy may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Alzheimer's Research & Therapy. A list of articles recently press-released by journals published by BioMed Central is available here. Copyright Authors of research articles published in Alzheimer's Research & Therapy retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright and license agreement). For further information about the advantages of publishing in a journal from BioMed Central, please click here.   Instructions to Authors Instructions for authors Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases. Each article type published by Alzheimer's Research & Therapy follows a specific format, as detailed in the corresponding instructions for authors; please choose an article type from the list on the left to view the instructions for authors. Please note that Commentary, Debate, Editorial, Letter, Meeting report, Review and Viewpoint are usually commissioned, but suggestions for these article types are welcome. The instructions for authors includes information about preparing a manuscript for submission to Alzheimer's Research & Therapy, criteria for publication and the online submission process. Other relevant information about the journal's policies, the refereeing process and so on can be found in 'About this journal'. Alzheimer's Research & Therapy publishes the following article types: Research articles Commentaries Debates Editorials Letters to the editor Meeting reports Open comments Reviews Viewpoints We use plagiarism detection This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE). Authors and referees are asked to declare any competing interests. Copyright for research articles rests with the authors. For more information on copyright of research articles, see our publisher's copyright and license policy. Copyright of all other articles rests with the publisher, BioMed Central. Editorial Board Editors-in-Chief Douglas R Galasko University of California, San Diego, United States of America Todd E Golde University of Florida, United States of America Philip Scheltens VU University Medical Center, Netherlands Editorial Board Paul Aisen University of California, San Diego, United States of America Kevin Barnham The University of Melborne, Australia Randall Bateman Washington University, United States of America Sandra E Black University of Toronto, Canada Kaj Blennow Göteborg University, Sweden Carol Brayne University of Cambridge, United Kingdom Alistair Burns University of Manchester, United Kingdom Rachelle Doody Baylor College of Medicine, United States of America Howard Fillit Alzheimer's Drug Discovery Foundation, United States of America Nick Fox University College London, United Kingdom Alison Goate Washington University, United States of America Jurgen Goetz University of Sydney, Australia Neill R Graff-Radford Mayo Clinic, Jacksonville, United States of America John Hardy University College London, United Kingdom Suzanne Hendrix Pentara Corporation, United States of America Clive Holmes University of Southampton, United Kingdom Takeshi Iwatsubo University of Tokyo, Japan Jianping Jia Xuan Wu Hospital of Beijing Capital Medical University, China SangYun Kim Seoul National University, Republic of Korea Matthew Lambon Ralph University of Manchester, United Kingdom Seth Love Frenchay Hospital, Bristol, United Kingdom Ian McKeith University of Newcastle, United Kingdom Bruce Miller University of California, San Francisco, United States of America Ralph A Nixon New York University, United States of America Agneta Nordberg Karolinska Institute, Sweden Ronald Petersen Mayo Clinic, Minnesota, United States of America Stuart Pickering-Brown Manchester University, United Kingdom Martin J. Prince King's College London, United Kingdom Gil Rabinovici University of California, San Francisco, United States of America Kenneth Rockwood Dalhousie University, Canada Martin Rossor University College London, United Kingdom Takaomi Saido RIKEN Brain Science, Japan Dennis Selkoe Brigham and Women's Hospital, United States of America Weihong Song University British Columbia, Canada Gabrielle Strobel Alzheimer Research Forum, United States of America Jinzhou Tian Beijing University of Chinese Medicine, China John Trojanowski University of Pennsylvania, United States of America Victor L. Villemagne The University of Melbourne, Australia Dominic Walsh Brigham and Womens Hospital, United States of America Donna M Wilcock University of Kentucky, United States of America Julie Williams Cardiff University, United Kingdom Bengt Winblad Karolinska Institute, Sweden Thomas Wisniewski New York University, United States of America Jian Zhi Wang Huazhong University of Science and Technology, Wuhan, China